may30,2013–GlaxoSmithKline (GSK) and Genmab (GEN) have announced positive results from Phase III study of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of chronic lymphocytic leukaemia (CLL) patients.
GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)
drugs
Comments Off on GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)
Jun 012013